PDE4 family inhibitors are effective inflammation inhibitors, which have been licensed to treat the inflammatory diseases ranging from chronic obstructive pulmonary disease (COPD) to arthritis (Wittmann and Helliwell, 2013; Li et al., 2018; Phillips, 2020). Here, PDE4A is linked to chronic obstructive pulmonary disease.